CN1420781A - 能够预防腹泻的双歧杆菌 - Google Patents
能够预防腹泻的双歧杆菌 Download PDFInfo
- Publication number
- CN1420781A CN1420781A CN00811244A CN00811244A CN1420781A CN 1420781 A CN1420781 A CN 1420781A CN 00811244 A CN00811244 A CN 00811244A CN 00811244 A CN00811244 A CN 00811244A CN 1420781 A CN1420781 A CN 1420781A
- Authority
- CN
- China
- Prior art keywords
- milk
- application
- food
- rotavirus
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 11
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 241000894006 Bacteria Species 0.000 claims description 26
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000008267 milk Substances 0.000 claims description 17
- 235000013336 milk Nutrition 0.000 claims description 17
- 210000004080 milk Anatomy 0.000 claims description 17
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 206010067470 Rotavirus infection Diseases 0.000 claims description 5
- 210000001842 enterocyte Anatomy 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 230000000741 diarrhetic effect Effects 0.000 claims description 3
- 235000011868 grain product Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims 2
- 244000005700 microbiome Species 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 241000702670 Rotavirus Species 0.000 description 23
- 239000001963 growth medium Substances 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000012010 growth Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000194036 Lactococcus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000005497 microtitration Methods 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000002953 anti-rotaviral effect Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010048832 Colon adenoma Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000617996 Human rotavirus Species 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000003037 histogenic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108700010850 rotavirus proteins Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical class NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000003085 Quassia amara Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Road Signs Or Road Markings (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
本发明涉及属于双歧杆菌的微生物的应用于制备一种载体，这种载体可用于治疗或预防腹泻。本发明也涉及含有这样的微生物的食物或药品的组合物。
Description
本发明涉及将非病原性微生物双歧杆菌类用于制备一种载体和加入食品或药物来治疗或预防轮状病毒引起的腹泻，以及涉及含有此微生物的食品或药物组合物。
很早以来人们就知道产生主要代谢组合物乳酸的生物体。在牛奶或牛奶处理工厂中，活着或腐烂的植物中，也可在人和动物的肠子中发现这些细菌。这些被概括为术语“乳酸细菌”的微生物，代表了一组相当不同类的细菌包括例如乳球菌属(Lactococcus)、乳杆菌属(Lactobacillus)，链球菌(Streptococcus)、双歧菌属(Bifidobacterium)、片球菌属(Pediococcus)。
乳酸细菌作为低pH值条件下保存食物的发酵剂使用，发酵产物的作用抑制有害细菌的生长。另外，乳酸细菌也用于制作不同的乳制品例如奶酪、酸奶酪和其他发酵的奶制品。
近期，乳酸细菌的一些菌株显示出对人和动物的吸收颇有价值的特性，引起了人们的密切关注。特别是，特殊的乳酸菌或双歧菌的菌株被发现能够在肠内膜上定居并且有助于维持人和动物的健康。
在这方面，欧洲专利EP0768375公开了双歧菌的特异性菌株，这种菌株能够灌输进入肠内并且粘附在肠细胞上。报道说这些双歧细菌有助于免疫功能，能够竞争性抑制病原性细菌对肠内细胞的粘附，有助于维持生物个体的健康。
最近几年的科研集中在乳酸细菌作为益生菌试剂的潜在应用。益生菌被认为是能通过保持肠内自然微生物区系促进生物个体健康的可生长的微生物制剂。微生物制剂通常被认为是益生菌也就是这种有效的微生物并且人们已经知道了它们作用的模式。益生菌贴附在肠粘膜上，在肠道内建群并且防止有害微生物在其上粘附。对于它们在肠内发挥作用的至关重要的先决条件是它们必须以一种适当的能存活的方式粘附到内脏的粘膜上而且在胃肠上部不被消灭，特别是不受胃内低pH区域的影响。
在这方面，作为这样的一种益生菌，WO97/00078公开了一种特异性菌株，称为乳酸菌GG(ATCC53103)。在防止或治疗食物诱发的过敏反应的方法中特定的使用这种微生物，也就是将其和已经经过用胃蛋白酶和/或胰岛素以及进行水解处理的食品给药于受体。所选择的乳酸菌菌株显示了粘附和生长性能及蛋白酶体系，以至于含在将被给药的食物的蛋白质通过被这种特殊的乳酸菌分泌的蛋白酶进一步水解。这份文件所讨论的方法最终导致蛋白质被内脏消化，没有显示出存在任何引起过敏的物质。
更进一步，在EP 0 577 903参考资料中采用了这种乳酸菌，它具有取代幽门螺杆菌的能力，幽门螺杆菌公认是引起溃疡的原因，上述制备可以治疗和预防幽门螺杆菌引起的溃疡。
乳酸菌特殊菌株显示出有价值的特性，现有技术目的在于希望发现细菌菌株能够有益于人类和/或动物的健康的其它的特性。
因此，本发明要解决的问题是提供另外的乳酸菌，它对生物体的摄食机能产生有益的作用。
在导致本发明的研究过程中，双歧杆菌类微生物没有被确定的性质现在被令人惊奇的发现了。本发明提供了属于双歧菌且能够基本上防止轮状病毒感染肠内细胞的微生物在用于腹泻的治疗或护理的载体中的应用。
所用的双歧杆菌优选从青春双歧杆菌(Bifidobacterium adolescentis)的或长双歧杆菌(Bifidobacterium longum)中选择组成，优选青春双歧杆菌，更优选双歧杆菌CNCM I-2168。
微生物可以用于一种可吸收的载体制备，例如牛奶、酸奶酪、凝乳、发酵奶、奶基发酵产品、发酵谷类产品、奶粉(milk based powders)、婴儿食品或宠物食品，且以大约105cfu/g到1011cfu/g的量包含在载体中。本发明采用的缩写cfu的意思是“菌落形成单位”，定义为琼脂板上的微生物计数所表示的细菌细胞的数目。
本发明也提供一种食品或药物组合物，含有至少一种双歧杆菌菌株，能够基本上防止肠细胞被轮状病毒感染。
本发明制备的食物组合物至少使用一种双歧杆菌菌株并以大约105cfu/g到1011cfu/g的含量，和合适的载体混合在一起，优选含量为大约106cfu/g到1010cfu/g，更优选大约为107cfu/g到109cfu/g.。
药品可以以片剂、液体细菌悬浮液、口服补充剂(oral supplement)、湿口服补充剂、干管饲或湿管饲等形式制备，所用的双歧杆菌菌株的含量高达1012cfu/g，优选大约107cfu/g到1011cfu/g，更优选107cfu/g到1010cfu/g。
微生物可以进一步被配制于载体内，以获得所希望的释放模式如胶囊剂等等。依据本领域技术人员的目的，可以选择适当的赋形剂和/或添加剂。
微生物在生物体肠内的活性当然取决于剂量。也就是分别通过上述食品或药物组合物摄入的微生物越多，保护和/或治疗的作用越高。由于所用的微生物对于人类或动物无害，实际上是从自然环境中分离出来的，也就是从婴儿的粪中分离出来的，加入的量高，生物体肠内微生物建群的比例也就高。
在这些图中
图1显示用于评价细菌菌株对轮状病毒的保护特性的细胞培养物的图例说明。
在本发明的广泛研究时，发明人调查了从婴儿粪便中分离的不同细菌菌株或从美国组织及细胞保藏中心获得不同的细菌菌株(ATCC15704)。检验这些不同的菌株防止肠细胞被轮状病毒引起腹泻的能力。
由于具有抑制轮状病毒的性能，几种细菌包括双歧杆菌属、乳球菌属、链球菌属类被筛选。用三种轮状病毒的血清型进行抑制性能试验，这三种轮状病毒血清类型代表了人类病毒腹泻的主要病原因子(血清型G1、G3和G4)。
各种乳酸细菌在适当的培养基中生长，例如在它们适合的培养基MRS、Hugo-Jago或M17培养基中，最佳的生长温度30到40℃。在这些细菌稳定生长后采用离心分离和在生理食盐溶液中重新悬浮收集这些细菌。这些不同试验之间中的细菌细胞被冷冻储存(-20℃)。
通过融合细胞单层的感染制备各种轮状病毒原种。在感染之前培养这些轮状病毒。这些细胞用20个组织培养感染剂量感染。
为了评估抗轮状病毒的特性采用了两种不同的方案。一个方案直接检验和轮状病毒直接作用的这些不同细菌菌株，而同时另一个方案使这些菌株和细胞轮状病毒的受体交互作用并筛选这些细菌。
第一个方案涉及采用不同的轮状病毒菌株与各自的细菌悬浮液相接触并在在合适的培养基中培养。然后将这种病毒-细菌混合物施加在人类未分化的结肠腺瘤细胞HT-29的单层细胞上(肠内上皮细胞系)并连续培养。然后检验病毒复制。
第二个方案涉及首先将各自的细菌悬浮液和人类未分化的结肠腺瘤细胞HT-29一起培养然后再加入这种病毒。在连续培养后检验病毒复制。
轮状病毒的复制很容易采用感染细胞中的轮状病毒蛋白质的组织免疫着色法来检测。
当和轮状病毒加上指定的细菌一起培养的细胞培养基中的感染细胞与仅与轮状病毒一起培养的细胞相比时感染细胞的数目减少到90％时，显然轮状细胞的抑制作用被施加于给定的细菌。
总数超出260种的不同的细菌菌株中只有4种具有抑制轮状病毒复制的作用。这些不同细菌属于双歧杆菌属的亚种青春双歧杆菌或长双歧杆菌。属于青春双歧杆菌的已命名为Bad4，根据布达佩斯条约被保存并获得保存号CNCM I-2168。这种菌株证明能够极其有效的防止人类细胞被轮状病毒感染。本发明将采用举例的方法描述。
培养基和溶液
MRS(Difco)，
Hugo-Jago(蛋白胨Difco 30g/l，酵母提取物Difco 10g/l，乳糖Difco 5g/l，KH2PO45g/l，牛肉汁Difco 2g/l，琼脂Difco 2g/l)
M17(Difco)
M199(Seromed)
Ringer溶液(Oxoid)
PBS(NaCl 8g/l，KCl 0.2g/l，Na2HPO4 1.15g/l，KH2PO4 0.2g/l))
蛋白胨磷酸盐肉汤(流体)
胰酶-乙二胺四乙酸溶液(黏液)
从美国费城儿童医院P.A.Offit获得人类轮状病毒Wa(G1血清型)和猿的轮状病毒SA-11(G3血清型)。从美国国立卫生研究所Bethesda，A.Kapikian获得DS-1xRRV重排列体(reassortant)病毒。从德国慕尼黑大学P.Bachmann获得血清型人类轮状病毒Hochi。
实施例1
从婴儿粪便中分离乳酸菌
从15到27天大的健康婴儿的尿布收集新鲜的粪便。1克新鲜粪便在无氧的条件下送到实验室在Ringer溶液系列稀释样品之后，在2小时内进行微生物分析，并涂在选择性培养基上。在37℃温度下在加入抗菌素的MRS琼脂(磷霉素80μg/ml，磺胺甲基异噁唑新明磺93pg/ml，甲氧苄胺嘧啶5ug/ml)培养48小时，用于分离乳酸细菌。随机提取并提纯菌体。进行分离株的生理学和遗传学特征的分析。在这项试验中也使用了获自ATCC(ATCC15704)的另一种菌株，对应于本发明优选的菌株Bad4。
实施例2
细胞中抗轮状病毒活性的菌株试验
由双歧杆菌属、乳球菌属和链球菌属组成的几种属的细菌被选出并检测其中显示出在细胞培养基抑制试验中具有抗轮状病毒活性的成员(见下述1st和2st方案)。乳球菌属采用一个种(乳酸乳球菌)由两个亚种组成(乳酸乳球菌乳亚种和乳酸乳球菌乳脂亚种)(Lc.lactis supsp.lactis and cremoris)。试验了总共30个菌株。链球菌属采用一个种(嗜热链球菌(S.thermophilus))的45个菌株。明串珠菌属(Leuconostoc)和丙酸菌属(Propionibacterium)由一个种(6个菌株)代表，而肠球菌和葡萄球菌属(Staphylococcus)每一种采用两个种类代表，总共17个菌株。
总共260个细菌菌株用于试验轮状病毒的活性。
1 st 方案：
30ul的各自细菌悬浮液(含平均3×106细菌)和70u.l M199培养基补充了10％的蛋白胨磷酸盐肉汤(流体)和5％胰酶-EDTA溶液(黏液)混合，再加入100μl补充M199培养基中的病毒。这种病毒-细菌混合物在4℃培养1小时，37℃培养1小时。作为融合单层细胞在96-well微量滴定板中(在M99培养基中用10％蛋白胨磷酸盐肉汤(流体)和5％胰岛素-EDTA溶液(黏液)用PBS冲稀1∶4补充)生长的人类未分化结肠瘤细胞HT-29用磷酸盐缓冲剂盐水(PBS，Ph7.2)洗三次。上述工艺混合的病毒和细菌混合物被转到这些细胞中并在微量滴定板中在CO2培养箱中培养18个小时。病毒的复制按照如下描述进行检验。
2 nd 方案：
30ul细菌悬浮液和加有10％的蛋白胨磷酸盐肉汤(流体)、5％胰酶-EDTA溶液(黏液)的70ul M199培养基混合，直接加到生长的HT-29细胞上并按照1st方案描述的方法在微量滴定板中进行预处理。在37℃下培养1小时后，将M199培养基中的100μl的病毒加入到微量滴定板中的细胞上。在CO2培养箱(Heraeus)中连续培养18个小时。复制病毒按照如下所述进行检验。
复制轮状病毒采用在后面将描述的感染细胞的轮状病毒蛋白质组织免疫着色进行检验。
在感染一天后，从微量滴定板去除细胞培养基并用无水乙醇固定细胞10分钟。去除乙醇并用PBS缓冲剂洗这些板三次。(主要直接抗VP6蛋白质)兔产生的50ul抗轮状病毒血清(从洛桑大学ISREC获得)在PBS中稀释1∶2000倍加入每个孔并用盖子盖上防止干燥，在37℃培养1小时。然后清除抗体血清并用PBS清洗三次。然后抗兔免疫球蛋白G(IgG)的山羊抗血清和过氧物酶(GAR-IgG-PO；Nordic)稀释1∶500倍的PBS加入到每个孔中，这些滴定板在37℃培养1小时。血清清除，滴定板再用PBS清洗三次。然后100pLI的下述混合物加入每一个孔中：0.05M的Tris盐酸(pH7.8)，1ml H2O2(30％suprapur，用水冲稀1∶600倍，Merck)和200μl 3-氨基-9-乙基咔唑(0.1g/10ml的乙醇在-80℃储存在200μl aliquots；A-5754；Sigma)。这些滴定板在室温至少培养30分钟。去除培养基然后注入200ul的H2O来停止反应。用倒置显微镜(Diavert；Leitz)计数感染细胞灶。
只有非常少的细菌菌株和轮状病毒发生作用。260个细菌细胞的4种至少在第一个方案中抑制轮状病毒复制。青春双歧杆菌CNCM I-2168(Bad4)有极强的抗血清型1轮状病毒、血清型3轮状病毒SA-11和血清型4轮状病毒Hochi的活性。
根据在＂Genera of lactic acid bacteria＂，Ed.B.J.B.Wood and W.H.Holzapfel，Blackie A & P.公开的方法，Bad4是革兰氏阳性和过氧化氢酶阴性菌，在发酵时不产生CO2并产生L(+)乳酸。
134表
| 申请人或代理人挡案号 | 国际申请号 |
关于微生物保藏的说明
(细则13之二)
| A.对说明书第 4 页，第10 行所述的微生物的说明 |
| B.保藏事项 |
| 保藏单位名称 国立巴斯德研究所微生物培养物保藏中心 |
| 保藏单位地址(包括邮政编码和国名)25，Rue du Docteur RouxF-75724 Paris Cedex 15 |
| 保藏日期 1999年3月15日 保藏编号 NCC 251-I-2168 |
| C.补充说明(必要时) |
| D.本说明是为下列指定国作的(如果说明不是为所有指定国而作的) |
| E.补充说明(必要时) |
| 下列说明将随后向国际局提供(写出说明的类别，例如：“保藏的编号”) |
PCT/RO/134表(1992年7月)
Claims (9)
1.属于双歧杆菌属的能够防止轮状病毒感染肠细胞的乳酸细菌在制备一种可以治疗和预防腹泻的载体中的应用。
2.权利要求1的应用，其中双歧杆菌选自由长双歧杆菌或青春双歧杆菌组成的组。
3.权利要求1的应用，其中双歧杆菌是双歧杆菌CNCM I-2168。
4.上述任一权利要求的应用，其中双歧杆菌含在可吸收的载体中。
5.权利要求5的应用，其中双歧杆菌含在载体中的量从大约105到大约1012cfi/g载体。
6.按照权利要求4或5的应用，其中载体是选自奶、干酪、凝乳、酸奶酪、奶基发酵产品、冰激凌、发酵谷类产品、奶粉、婴儿食品或宠物食品的食物组合物。
7.食品或药物组合物，至少含有一种能够防止轮状病毒感染肠细胞的双歧杆菌菌株。
8.按照权利要求7的组合物，选自奶、干酪、凝乳、酸奶酪、奶基发酵产品、冰激凌、发酵谷类产品、奶粉、婴儿食品或宠物食品、片剂、液体细菌悬浮液、干口服补充剂、湿口服补充剂、干管饲或湿管饲。
9.按照权利要求7组合物为片剂、液体细菌悬浮液、干口服补充剂、湿口服补充剂，干管饲或湿管饲的形式。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99115501 | 1999-08-05 | ||
| EP99115501.1 | 1999-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1420781A true CN1420781A (zh) | 2003-05-28 |
| CN1198631C CN1198631C (zh) | 2005-04-27 |
Family
ID=8238732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008112444A Expired - Fee Related CN1198631C (zh) | 1999-08-05 | 2000-07-26 | 双歧杆菌在制备预防腹泻药物中的用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6998119B1 (zh) |
| EP (1) | EP1353681B1 (zh) |
| CN (1) | CN1198631C (zh) |
| AT (1) | ATE380033T1 (zh) |
| AU (1) | AU6698000A (zh) |
| BR (1) | BR0012973B1 (zh) |
| CA (1) | CA2378426C (zh) |
| DE (1) | DE60037343T2 (zh) |
| DK (1) | DK1353681T3 (zh) |
| ES (1) | ES2296635T3 (zh) |
| HK (1) | HK1056315A1 (zh) |
| PT (1) | PT1353681E (zh) |
| TR (1) | TR200200300T2 (zh) |
| WO (1) | WO2001010453A2 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884782A (zh) * | 2010-06-29 | 2010-11-17 | 南昌大学 | 长双歧杆菌粘附抑制蛋白Aip在防治腹泻中的应用 |
| CN103082294A (zh) * | 2013-01-21 | 2013-05-08 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗腹泻组合物中的应用 |
| CN103798391A (zh) * | 2014-03-06 | 2014-05-21 | 吉林修正修元生物科技有限公司 | 一种治疗婴童乳糖不耐症、腹泻的食品及其制备方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITBO20020564A1 (it) * | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | Bifidobatteri e preparazioni che li contengono. |
| KR100492455B1 (ko) * | 2003-09-26 | 2005-05-30 | 주식회사 비피도 | 로바타바이러스 억제활성을 갖는 신균주 비피도 박테리움 롱검 에이알81 및 이로부터 분리된 활성단백질 |
| EP2522358B1 (en) | 2007-06-27 | 2016-11-09 | Laboratorios Ordesa, S.l. | Peptides against rotavirus infection |
| EP2206506A1 (en) * | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Probiotic formulations |
| EP2455094A1 (en) | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
| CN110839698A (zh) * | 2019-11-29 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | 一种组合物及其食品用途 |
| CN116121119B (zh) * | 2022-11-30 | 2024-01-26 | 天津小薇生物科技有限公司 | 一种治疗腹泻的长双歧杆菌bc012及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0768375T4 (da) * | 1992-07-06 | 2002-09-16 | Nestle Sa | Mælkesyrebakterier |
| DE69223615T2 (de) | 1992-07-06 | 1998-04-09 | Nestle Sa | Lactobacillus Acidophilus enthaltende Antigastritis-Mittel |
| AUPM823094A0 (en) * | 1994-09-16 | 1994-10-13 | Goodman Fielder Limited | Probiotic compositions |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US5902578A (en) | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
| EP0904784A1 (en) | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
-
2000
- 2000-07-26 CN CNB008112444A patent/CN1198631C/zh not_active Expired - Fee Related
- 2000-07-26 CA CA2378426A patent/CA2378426C/en not_active Expired - Fee Related
- 2000-07-26 AU AU66980/00A patent/AU6698000A/en not_active Abandoned
- 2000-07-26 EP EP00954568A patent/EP1353681B1/en not_active Expired - Lifetime
- 2000-07-26 DE DE60037343T patent/DE60037343T2/de not_active Expired - Lifetime
- 2000-07-26 WO PCT/EP2000/007207 patent/WO2001010453A2/en active IP Right Grant
- 2000-07-26 US US10/049,368 patent/US6998119B1/en not_active Expired - Fee Related
- 2000-07-26 DK DK00954568T patent/DK1353681T3/da active
- 2000-07-26 PT PT00954568T patent/PT1353681E/pt unknown
- 2000-07-26 ES ES00954568T patent/ES2296635T3/es not_active Expired - Lifetime
- 2000-07-26 TR TR2002/00300T patent/TR200200300T2/xx unknown
- 2000-07-26 BR BRPI0012973-9B1A patent/BR0012973B1/pt not_active IP Right Cessation
- 2000-07-26 AT AT00954568T patent/ATE380033T1/de active
-
2003
- 2003-11-25 HK HK03108600A patent/HK1056315A1/xx unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884782A (zh) * | 2010-06-29 | 2010-11-17 | 南昌大学 | 长双歧杆菌粘附抑制蛋白Aip在防治腹泻中的应用 |
| CN101884782B (zh) * | 2010-06-29 | 2015-09-16 | 南昌大学 | 长双歧杆菌粘附抑制蛋白Aip在防治腹泻中的应用 |
| CN103082294A (zh) * | 2013-01-21 | 2013-05-08 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗腹泻组合物中的应用 |
| CN103798391A (zh) * | 2014-03-06 | 2014-05-21 | 吉林修正修元生物科技有限公司 | 一种治疗婴童乳糖不耐症、腹泻的食品及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1353681A2 (en) | 2003-10-22 |
| PT1353681E (pt) | 2008-02-25 |
| WO2001010453A3 (en) | 2003-08-21 |
| US6998119B1 (en) | 2006-02-14 |
| DE60037343D1 (de) | 2008-01-17 |
| ES2296635T3 (es) | 2008-05-01 |
| TR200200300T2 (tr) | 2003-03-21 |
| CA2378426C (en) | 2010-03-23 |
| WO2001010453A2 (en) | 2001-02-15 |
| HK1056315A1 (en) | 2004-02-13 |
| CN1198631C (zh) | 2005-04-27 |
| EP1353681B1 (en) | 2007-12-05 |
| ATE380033T1 (de) | 2007-12-15 |
| BR0012973A (pt) | 2002-04-30 |
| AU6698000A (en) | 2001-03-05 |
| DE60037343T2 (de) | 2008-11-27 |
| DK1353681T3 (da) | 2008-03-10 |
| BR0012973B1 (pt) | 2013-12-17 |
| CA2378426A1 (en) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111484957B (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
| CN100378214C (zh) | 益生细菌:发酵乳杆菌 | |
| AU760398C (en) | A beneficial microbe composition, new protective materials for the microbes, the method to prepare and uses thereof | |
| CN100386427C (zh) | 双歧杆菌和含有它们的制品 | |
| Kleeman et al. | Adherence of Lactobacillus species to human fetal intestinal cells | |
| AU751284B2 (en) | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain | |
| US5951977A (en) | Competitive exclusion culture for swine | |
| CN101068918B (zh) | 具有减少身体脂肪活性的鼠李糖乳杆菌以及包含它们的食品 | |
| CN114774313B (zh) | 鼠李糖乳杆菌LRa05在制备缓解便秘制品或调解肠道菌群制品方面的用途 | |
| Michel et al. | Isolation of an Acanthamoeba strain with intracellular Burkholderia pickettii infection | |
| CN112746034B (zh) | 一种协同抑制幽门螺旋杆菌的鼠李糖乳杆菌lr863和鼠李糖乳杆菌lr519及其应用 | |
| CN113122467B (zh) | 一种副干酪乳杆菌及其组合物 | |
| CN1369005A (zh) | 预防病原性细菌引起的腹泻的新双歧杆菌 | |
| GB2338244A (en) | A beneficial microbe composition, new protective materials for the microbes, the method to prepare the same and uses thereof | |
| CN114292781B (zh) | 一种长双歧杆菌sysu-02及其应用 | |
| CN1198631C (zh) | 双歧杆菌在制备预防腹泻药物中的用途 | |
| CN114292779A (zh) | 一种副干酪乳杆菌冻干粉、其应用及制备方法 | |
| CN116574648A (zh) | 一种植物乳杆菌及其在缓解便秘中的应用 | |
| CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
| CN111454862B (zh) | 一种具有口腔保健功能的副干酪乳杆菌冻干粉、制备方法及应用 | |
| CN116746683A (zh) | 防消化不良胀气、促吸收的动物双歧杆菌乳亚种bal-28及发酵产物、菌群cw和应用 | |
| CN107325995A (zh) | 一种唾液链球菌菌株及其应用 | |
| CN114686393B (zh) | 一种动物双歧杆菌乳亚种及其组合物 | |
| JP2004018469A (ja) | 抗アレルギー剤 | |
| CN109517765A (zh) | 一种粪链球菌及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050427 Termination date: 20140726 |
|
| EXPY | Termination of patent right or utility model |